Immuron North American Travelan® Sales up 494% and Global sales up 431%

Highlights: North American FY22 Travelan® sales increased by +494% to $0.6M Global sales increased by 431% to $0.9M Australian FY22 sales increased by 318% to $0.3M MELBOURNE, Australia, July 11, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN ), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce the FY22 sales results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan® and Protectyn®. North America, Travelan® sales were up by 494%, reaching AU $0.6M in ... Full story available on Benzinga.com